Arcturus Therapeutics maintained Outperform rating by Leerink
Leerink Partners maintained an Outperform rating on Arcturus Therapeutics, per Benzinga ratings actions.
Story updates
12:45:52 PM UTC
SquawkNews
Arcturus Therapeutics Price Target Raised to $19.00/Share From $13.00 by Leerink Partners